Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Among authors: jager d. Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. Ann Oncol. 2017. PMID: 27687312 Free article. No abstract available.
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW. Lorenzen S, et al. Among authors: jager d. BMC Cancer. 2011 Jun 24;11:266. doi: 10.1186/1471-2407-11-266. BMC Cancer. 2011. PMID: 21702914 Free PMC article.
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D. Berger AK, et al. Among authors: jager d. BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108. BMC Cancer. 2012. PMID: 22439666 Free PMC article. Clinical Trial.
[Urology in the concept of comprehensive cancer centers].
Hadaschik B, Pahernik S, Grüllich C, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. Hadaschik B, et al. Among authors: jager d. Urologe A. 2013 Sep;52(9):1283-9. doi: 10.1007/s00120-013-3313-3. Urologe A. 2013. PMID: 23942742 Review. German.
Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer center.
Vallet S, Pahernik S, Höfner T, Tosev G, Hadaschik B, Duensing S, Sedlaczek O, Hohenfellner M, Jäger D, Grüllich C; Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany. Vallet S, et al. Among authors: jager d. Clin Genitourin Cancer. 2015 Jun;13(3):e145-52. doi: 10.1016/j.clgc.2014.12.012. Epub 2014 Dec 30. Clin Genitourin Cancer. 2015. PMID: 25596830
High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J. Weber T, et al. Among authors: jager d. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):489-98. doi: 10.1007/s00259-015-3175-6. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26341366
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Kordes M, et al. Among authors: jager d. Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19. Leukemia. 2016. PMID: 26582644
574 results